27 October 2020
Latham & Watkins Advises Sobi on Strategic Licensing and Collaboration Agreement with Apellis Pharmaceuticals Inc
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Steven Chinowsky Lead | Latham & Watkins LLP | Partner | life sciences licensing | San Diego |
| Frances Stocks Allen Lead | Latham & Watkins LLP | Associate | life sciences licensing | London |
| Oliver Mobasser | Latham & Watkins LLP | Associate | Not stated | London |
| Eliot Choy | Latham & Watkins LLP | Counsel | Not stated | New York |
| Darryl Steensma | Latham & Watkins LLP | Counsel | Not stated | San Diego |
| Oscar Bjartell | Latham & Watkins LLP | Associate | Not stated | London |
| Robert Yeh | Latham & Watkins LLP | Associate | Not stated | San Diego |
| Kirt Switzer | Latham & Watkins LLP | Partner | tax | San Francisco |
Stated terms
- Stated value
- USD 250m (US$250 million)
- What the figure measures
- Total transaction value
- Client
- SobiJoint venture party
- Counterparties
- Apellis Pharmaceuticals, Inc. (Joint venture party)